<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784589</url>
  </required_header>
  <id_info>
    <org_study_id>2008/068/HP</org_study_id>
    <nct_id>NCT00784589</nct_id>
  </id_info>
  <brief_title>Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus</brief_title>
  <acronym>Rituximab 3</acronym>
  <official_title>Comparison Between Monoclonal Antibody CD20 Treatment (Rituximab (mabthéra))and General Corticotherapy Treatment in Patients With Pemphigus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pemphigus is a severe and sometimes life-threatening disease with a mortality rate between 5
      and 10 percent depending on the severity of disease and age of patients.

      The standard of care is high doses of corticosteroids (CS) (usually, prednisone, 1 to 1.5.
      mg/kg/day, which are often associated with immunosuppressive drugs i.e., azathioprine,
      mycophenolate mofetil, cyclophosphamide, cyclosporine, although only one randomised study has
      demonstrated the superiority of the combination of corticosteroids and immunosuppressive
      drugs as compared to corticosteroids alone (9). Because of the low frequency of the disease,
      control trials are difficult to conduct. Evaluation of the different treatment regimens
      proposed, i;e; corticosteroids alone, CS and immunosuppressive drugs, IV immunoglobulins or
      new therapeutic regimens such as rituximab (an anti-CD20 monoclonal antibody directed against
      B- lymphocytes) or immunoadsorbtion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with pemphigus controlled 24 months after the start of Rituximab treatment</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with pemphigus with both cutaneous and mucosal lesions healing after 6 months of rituximab treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pemphigus Disease</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>General Corticotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>General Corticotherapy</intervention_name>
    <description>for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,</description>
    <arm_group_label>Corticotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;=18 and &lt;= 80years

          -  consent obtained from patient

          -  effective female contraceptive method for women in procreate age

          -  new case of pemphigus vulgaris (PV) or pemphigus foliaceus (PF)

        Exclusion Criteria:

          -  pemphigus vulgaris (PV) or pemphigus foliaceus (PF) treated

          -  pregnant woman or nursing mother

          -  woman able to have a baby and without contraception during the clinical trial period

          -  age &lt; 18 or &gt; 80

          -  karnovsky &lt; 50%

          -  serious antecedents of allergy or anaphylactic reaction with human monoclonal antibody

          -  patient with depletion lymphocytic treatment in the next month

          -  unstable angina or ischemic heart disease

          -  cardiac insufficiency

          -  cardiac rhythm trouble uncontrolled

          -  positive HIV serology

          -  positive hepatitis B and / or C serology

          -  no consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal JOLY, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Dermatologique - Hôpitaux de Rouen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Rouen - Hôpitaux de Rouen</name>
      <address>
        <city>Rouen</city>
        <state>Seine Maritime</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2008</study_first_submitted>
  <study_first_submitted_qc>November 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2008</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corticothérapy</keyword>
  <keyword>Rituximab</keyword>
  <keyword>therapeutic efficacity</keyword>
  <keyword>therapeutic tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

